SECURITIES AND EXCHANGE COMMISSION
to Section 13 or 15(d) of the Securities Exchange Act of 1934
of report (date of earliest event reported): February 1, 2019
Pharmaceutical Research Corp.
Name of Registrant as Specified in its Charter)
File No.: 0-54856
Employer Identification No.)
Ben Gurion Street, Ramat Gan, Israel
of Principal Executive Offices)
Telephone Number, including area code: 972 (72) 2608004
name or former address, if changed since last report.)
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
growth company [ ]
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
February 1, 2019, OWC Pharmaceutical Research Corp. (the “Registrant”) appointed Ms. Sigal Russo as Chief Financial
Officer of the Registrant and its wholly-owned Israeli subsidiary, One World Cannabis Ltd. Sigal Russo will replace Yossi Dagan
who resigned as Chief Financial Officer of the Company on February 1, 2019, effective immediately. Mr. Dagan is leaving the Company
on amicable terms to pursue other opportunities.
Russo, aged 40, is a Certified Public Accountant licensed in Israel. Most recently, Ms. Russo served as Senior Director of Finance
of Rosetta Genomics Ltd. (NASDAQ: ROSG), a molecular diagnostics company, where she was responsible for all aspects of Rosetta
Genomics’ finances, and reported to the chief financial officer. Ms. Russo served in various roles at Rosetta Genomics
since 2008. Prior to her tenure at Rosetta Genomics, Ms. Russo was an audit manager at Ernst & Young in Israel, specializing
in audits of companies from various fields, both publicly traded and privately owned American and Israeli entities, from 2004
to 2008. Ms. Russo holds a BA in Economics and Accounting, from the Ruppin Academic College.
OWC Pharmaceutical Research Corp
Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively “OWC”
or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments
for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines.
is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at
leading Israeli hospitals and scientific institutions and led by internationally renowned investigators.
Mordechai Bignitz, Chief Executive Officer - OWC Pharmaceutical research crop,
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Pharmaceutical Research Corp.
February 4, 2019